Evidence map›Paper›PMID 29731700›Full record

ArticleJOP : Journal of the pancreas2017

Preventing Post-ERCP Pancreatitis: The Role of Prophylactic Pancreatic Duct Stenting in the Rectal NSAID Era.

Noor-L-Houda Bekkali, Tom Thomas, Margaret Geraldine Keane, Sam Murray, Deepak Joshi, Ghassan Elsayed, Gavin James Johnson, Michael Huw Chapman, Stephen Paul Pereira, George John Mitchell Webster

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in JOP : Journal of the pancreas, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Noor-L-Houda BekkaliPancreaticobiliary Medicine Unit, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Tom ThomasUniversity of East Anglia, Norwich, United Kingdom.
Margaret Geraldine KeanePancreaticobiliary Medicine Unit, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Sam MurrayPancreaticobiliary Medicine Unit, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Deepak JoshiPancreaticobiliary Medicine Unit, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Ghassan ElsayedPancreaticobiliary Medicine Unit, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Gavin James JohnsonPancreaticobiliary Medicine Unit, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Michael Huw ChapmanPancreaticobiliary Medicine Unit, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Stephen Paul PereiraPancreaticobiliary Medicine Unit, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
George John Mitchell WebsterPancreaticobiliary Medicine Unit, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
University of East Anglia · GB

Funding

Small Molecule Enhancers of Photodynamic Therapy for Skin CancerP01CA084203 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Bryan Quilty Spring · 2001 to 2026
$27.9M
Department of Health PB-PG-0712-28114NCI NIH HHS P01 CA084203
6 · The paper itself

Abstract

backgroundRectal non-steroidal anti-inflammatory drug at endoscopic retrograde cholangiopancreatography is now the standard of care to reduce the risk of post-ERCP pancreatitis. Pancreatic duct stenting also reduces the risk of post- ERCP pancreatitis in high-risk patients, but failed pancreatic duct stenting carries an increased PEP rate (up to 35%). STUDY

aimTo assess the impact on post-ERCP pancreatitis of successful and unsuccessful pancreatic duct stent placement in the setting of universal rectal non-steroidal anti-inflammatory drug use.

methodsBetween 2013-2015, all patients undergoing endoscopic retrograde cholangiopancreatographys in our tertiary referral centre (where rectal non-steroidal anti-inflammatory drugs are used routinely) were included. The electronic patient's records were reviewed and the following parameters were analysed: indication for pancreatic duct stenting; deployment success; and adverse events.

resultsA total of 1633 endoscopic retrograde cholangiopancreatographys were performed, and pancreatic duct stenting was attempted in 324 cases (20%), with successful placement in 307 patients (95%). Contra-indications to non-steroidal anti-inflammatory drugs were found in 106 (6.5%) patients. Prophylactic stenting failed in 12 of 213 patients; of whom one patient developed post-ERCP pancreatitis (8%). Eighteen (9%) patients with prophylactic pancreatic duct stents developed post-ERCP pancreatitis compared to 1.4% without prophylactic stents (RR 8.4, p=0.04).

conclusionA lack of difference in post-ERCP pancreatitis in those who underwent successful, and unsuccessful, pancreatic duct stent placement may reflect the protective effect of non-steroidal anti-inflammatory drugs. This data adds to evidence suggesting that pancreatic duct stenting may be less important, even in high-risk patients, with the widespread use of non-steroidal anti-inflammatory drugs.

Indexed as

Pancreatic DuctsPancreatitis

Identifiers

PMID29731700
PMCPMC5933872
OpenAlexW2728041548

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.